Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants

Lymphoproliferative disorders after liver transplantation

“…Muti et al recently found that the serum IL10 level had better predictive value than EBV viral load [15]. Stable monoclonal gammopathy also seems to be highly predictive of PTLD [6]. The immunosuppressive regimen has an important role in PTLD, and especially the use of antilymphocytic serum [4] and tacrolimus in children [8,12].…”

The immunoglobulinopathies: From physiopathology to diagnosis

“…For example, it has been recently shown that the finding of multiple clonal Igs in recipients of liver transplant is a sensitive way to detect lymphoproliferative disorders associated with immunosuppression [82]. Finally, it is important to note that clonal imbalances of the production of Igs is a physiological process during the first years of life, and that the definition of the frontier between the normality and the abnormality of the clonality of Igs in plasma can be difficult in this setting [74].…”

Hepatitis C Virus Infection Can Affect Lymphoproliferative Disorders Only as a Cofactor for Epstein-Barr Virus in Liver Transplant Recipients: PTLD.Int Survey

“…10 ZiarkiewiczWróblewska et al 31 4 (1.9) 1 (1.5) 3 (2.1) 11 Mucha et al 8 2 (0.9) 1 (1.5) 1 (0.7) 12 Niedobitek et al 32 4 (1.9) 1 (1.5) 3 (2.1) 13 Dean et al 33 23 (10.8) 7 (10.3) 16 (11.1) 14 Baron et al 34 14 (6.6) 1 (1.5) 13 (9) 15 Ben-Ari et al 35 7 (3.3) 2 (2.9) 5 (3.5) 16 Koh et al 36 10 (4.7) 1 (1.5) 9 (6.3) 17 Baccarania et al 37 9 (4.2) 7 (10.3) 2 (1.4) 18 Bianchi et al 38 1 (0.5) 0 1 (0.7) 19 Burra et al 39 2 (0.9) 1 (1.5) 1 (0.7) 20 Lemoine et al 40 21 (9.9) 6 (8.8) 15 (10.4) 21 Cano et al 41 3 (1.4) 3 (4.4) 0 22 Dhillon et al 42 19 (9.0) 5 (7.4) 14 (9.7) 23 Sun et al 43 1 (0.5) 1 (1.5) 0 24 Pham et al 44 1 (0.5) 1 (1.5) 0 25 Nagarsheth et al 45 1 (0.5) 0 1 (0.7) 26 Hsi et al 46 2 (0.9) 1 (1.5) 1 (0.7) 27 Kogan-Liberman et al 47 2 (0.9) 0 2 (1.4) 28 Aseni et al 48 9 (4.2) 4 (5.9) 5 (3.5) 29 McCormack et al 49 4 (1.9) 1 (1.5) 3 (2.1) Total 212 (100) 68 (100) 144 (100) (32%) were HCV-positive PTLD, and the remaining 144 patients (68%) developed HCV-negative PTLD LT. Epstein-Barr virus was documented in 145 patients (68%), of whom, 112 (77%) were reported positive. Because methodologies differed among the published studies, not all our measures were available for all patients.…”